You are here Home Guidance and resources Generic Health Pty Ltd Regulatory activities for this sponsor. Listen Print Share Loading... Type Prescription medicine decision summary (1) (-) Prescription medicine decision summary (1) ARTG (170) ARTG (170) Cancellation by sponsor (114) Cancellation by sponsor (114) Prescription medicine registration (9) Prescription medicine registration (9) Cancellation or suspension (7) Cancellation or suspension (7) Australian Public Assessment Report (AusPAR) (1) Australian Public Assessment Report (AusPAR) (1) Section 14, TGO91 consent (1) Section 14, TGO91 consent (1) Show more Date 2023 (1) 2023 (1) Search Filters applied:Prescription medicine decision summaryClear all Sponsor content1 result(s) found, displaying 1 to 1 Teriparatide Lupin, Teriparatide GH and Teriparatide LAPL 18 April 2023 Prescription medicine decision summary TGA decision: Teriparatide Lupin and LAPL and GH (teriparatide acetate) are approved for the treatment of osteoporosis.
Teriparatide Lupin, Teriparatide GH and Teriparatide LAPL 18 April 2023 Prescription medicine decision summary TGA decision: Teriparatide Lupin and LAPL and GH (teriparatide acetate) are approved for the treatment of osteoporosis.